NG9 Stock Overview
Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NeoGenomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.00 |
| 52 Week High | US$18.60 |
| 52 Week Low | US$11.80 |
| Beta | 1.18 |
| 11 Month Change | 13.82% |
| 3 Month Change | -3.45% |
| 1 Year Change | -20.90% |
| 33 Year Change | -58.49% |
| 5 Year Change | -39.66% |
| Change since IPO | 4,017.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| NG9 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -7.9% | 0.8% | -0.2% |
| 1Y | -20.9% | 17.2% | 7.8% |
Return vs Industry: NG9 underperformed the German Healthcare industry which returned 18% over the past year.
Return vs Market: NG9 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| NG9 volatility | |
|---|---|
| NG9 Average Weekly Movement | 5.9% |
| Healthcare Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NG9 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NG9's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,100 | Chris Smith | www.neogenomics.com |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
NeoGenomics, Inc. Fundamentals Summary
| NG9 fundamental statistics | |
|---|---|
| Market cap | €1.82b |
| Earnings (TTM) | -€73.36m |
| Revenue (TTM) | €607.92m |
3.1x
P/S Ratio-25.4x
P/E RatioIs NG9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NG9 income statement (TTM) | |
|---|---|
| Revenue | US$644.12m |
| Cost of Revenue | US$363.69m |
| Gross Profit | US$280.43m |
| Other Expenses | US$358.16m |
| Earnings | -US$77.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 43.54% |
| Net Profit Margin | -12.07% |
| Debt/Equity Ratio | 59.5% |
How did NG9 perform over the long term?
See historical performance and comparison